CN117460698A - 表面修饰纳米粒子 - Google Patents

表面修饰纳米粒子 Download PDF

Info

Publication number
CN117460698A
CN117460698A CN202280040669.6A CN202280040669A CN117460698A CN 117460698 A CN117460698 A CN 117460698A CN 202280040669 A CN202280040669 A CN 202280040669A CN 117460698 A CN117460698 A CN 117460698A
Authority
CN
China
Prior art keywords
group
modified nanoparticle
boron
dnd
aromatic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280040669.6A
Other languages
English (en)
Chinese (zh)
Inventor
西川正浩
小松直树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daicel Corp
Kyoto University NUC
Original Assignee
Daicel Corp
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daicel Corp, Kyoto University NUC filed Critical Daicel Corp
Publication of CN117460698A publication Critical patent/CN117460698A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/25—Diamond
    • C01B32/28—After-treatment, e.g. purification, irradiation, separation or recovery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280040669.6A 2021-06-11 2022-06-09 表面修饰纳米粒子 Pending CN117460698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021098083 2021-06-11
JP2021-098083 2021-06-11
PCT/JP2022/023332 WO2022260136A1 (ja) 2021-06-11 2022-06-09 表面修飾ナノ粒子

Publications (1)

Publication Number Publication Date
CN117460698A true CN117460698A (zh) 2024-01-26

Family

ID=84424595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280040669.6A Pending CN117460698A (zh) 2021-06-11 2022-06-09 表面修饰纳米粒子

Country Status (6)

Country Link
US (1) US20240277848A1 (https=)
EP (1) EP4353680A4 (https=)
JP (1) JPWO2022260136A1 (https=)
CN (1) CN117460698A (https=)
TW (1) TW202317470A (https=)
WO (1) WO2022260136A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793185B2 (ja) * 2022-01-19 2026-01-05 国立大学法人金沢大学 修飾ナノダイヤモンドの製造方法
CN119173267A (zh) * 2022-05-20 2024-12-20 国立大学法人京都大学 表面修饰纳米金刚石
WO2025117963A1 (en) * 2023-11-30 2025-06-05 1S1 Energy, Inc. Boronic acid-functionalized carbon materials
WO2026005041A1 (ja) * 2024-06-28 2026-01-02 ＲａｄｉｏＮａｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 改変された修飾炭化ホウ素粒子およびそれを含む中性子捕捉療法用薬剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103043647A (zh) * 2012-12-26 2013-04-17 复旦大学 表面修饰氨基苯硼酸的纳米碳材料及其制备方法和应用
CN103877940A (zh) * 2012-12-19 2014-06-25 中国科学院大连化学物理研究所 4-巯基苯硼酸固定化氧化石墨烯复合纳米材料及制备和应用
JP2015147733A (ja) * 2014-02-04 2015-08-20 国立大学法人滋賀医科大学 抗癌剤が担持されたナノ粒子
CN110812490A (zh) * 2019-11-19 2020-02-21 南京智能高端装备产业研究院有限公司 棒状前药自递送系统及其制备方法和应用
US20200147218A1 (en) * 2018-11-13 2020-05-14 Uchicago Argonne, Llc Boron-10 containing biocompatible nanostructures
CN111699283A (zh) * 2018-02-08 2020-09-22 株式会社大赛璐 镀膜
WO2020246500A1 (ja) * 2019-06-05 2020-12-10 株式会社ダイセル 表面修飾ナノダイヤモンド及び表面修飾ナノダイヤモンドの製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345771B2 (ja) 2007-08-27 2013-11-20 公立大学法人大阪府立大学 ｐ−ボロノフェニルアラニンとソルビトールとを含有する液状組成物
JP5399118B2 (ja) 2009-04-13 2014-01-29 株式会社ダイセル 表面修飾ナノダイヤモンド及びその製造法
JP5614643B2 (ja) 2010-10-12 2014-10-29 国立大学法人滋賀医科大学 サイズ制御された表面修飾ナノダイヤモンド
JP6281991B2 (ja) * 2014-04-11 2018-02-21 国立研究開発法人産業技術総合研究所 ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法
WO2021039521A1 (ja) 2019-08-30 2021-03-04 株式会社ダイセル 表面修飾ナノダイヤモンドの製造法
JP6889937B2 (ja) 2019-10-15 2021-06-18 株式会社コナミアミューズメント 抽選装置
CN119173267A (zh) * 2022-05-20 2024-12-20 国立大学法人京都大学 表面修饰纳米金刚石

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103877940A (zh) * 2012-12-19 2014-06-25 中国科学院大连化学物理研究所 4-巯基苯硼酸固定化氧化石墨烯复合纳米材料及制备和应用
CN103043647A (zh) * 2012-12-26 2013-04-17 复旦大学 表面修饰氨基苯硼酸的纳米碳材料及其制备方法和应用
JP2015147733A (ja) * 2014-02-04 2015-08-20 国立大学法人滋賀医科大学 抗癌剤が担持されたナノ粒子
CN111699283A (zh) * 2018-02-08 2020-09-22 株式会社大赛璐 镀膜
US20200147218A1 (en) * 2018-11-13 2020-05-14 Uchicago Argonne, Llc Boron-10 containing biocompatible nanostructures
WO2020246500A1 (ja) * 2019-06-05 2020-12-10 株式会社ダイセル 表面修飾ナノダイヤモンド及び表面修飾ナノダイヤモンドの製造方法
CN110812490A (zh) * 2019-11-19 2020-02-21 南京智能高端装备产业研究院有限公司 棒状前药自递送系统及其制备方法和应用

Also Published As

Publication number Publication date
US20240277848A1 (en) 2024-08-22
TW202317470A (zh) 2023-05-01
WO2022260136A1 (ja) 2022-12-15
EP4353680A4 (en) 2026-04-22
EP4353680A1 (en) 2024-04-17
JPWO2022260136A1 (https=) 2022-12-15

Similar Documents

Publication Publication Date Title
CN117460698A (zh) 表面修饰纳米粒子
Wang et al. Cyanine-assisted exfoliation of covalent organic frameworks in nanocomposites for highly efficient chemo-photothermal tumor therapy
US9745273B2 (en) Phenazine derivatives as anti-neoplastic agents and anti-infective agents
CN109021026B (zh) 顺铂药物前体、制备方法和应用
KR102905133B1 (ko) Pegmema 및 약물 함유성 폴리머 세그먼트로 구성된 자가-조립된 다이블록 코폴리머
US12338244B2 (en) Temozolomide compounds, polymers prepared therefrom, and method of treating a disease
CN108727353B (zh) 联合光热治疗和化疗的ir820-ptx两亲性小分子前药及其纳米粒制备方法和应用
CN113264906A (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
CN108853512A (zh) 双药型顺铂/阿霉素－聚多巴胺前药纳米粒子的制备和抗肿瘤应用
Xu et al. A unique chemo-photodynamic antitumor approach to suppress hypoxia via ultrathin graphitic carbon nitride nanosheets supported a platinum (IV) prodrug
EP4527393A1 (en) Surface-modified nanodiamond
US11833128B2 (en) Ketone carbonyl-containing hydrophobic antitumor drug and conjugate thereof as well as nano preparation containing conjugate, preparation method therefor, and application thereof
KR101554703B1 (ko) 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법
US12595336B2 (en) Method for producing maleimide polyethylene glycol derivative
KR101883745B1 (ko) 공액화 고분자를 포함하는 나노입자 및 이의 용도
Li et al. Self-assembly of nanoparticles from cyclotriphosphazenes grafted with hexa-[p-(carbonyl tryptophan ethyl ester) phenoxy)] group
CN119823140B (zh) 一种gsh响应型西达本胺异二聚体纳米前药及其制备方法与应用
CN111285911B (zh) Gem-1mt两亲小分子化合物及其制剂、制备方法和应用
US20250206879A1 (en) Boronic acid-containing modified polyrotaxane
Thakur et al. Anti-cancer active nano carbon drug conjugate based on an Aryl Azide using the classical'click'chemistry.
Samuel Carbon-Based Nanomaterials and their Medical Applications
CN120904244A (zh) 靶向线粒体自噬的铁死亡前药化合物及其制备方法和应用
KR20240066975A (ko) 양이온성 지질 및 이의 제조방법
백승민 Synthesis of Stimuli-Responsive Pt-Nanocluster Assembly against Chemoresistant Hepatocellular Carcinoma
KR20220109877A (ko) 환원반응성 일산화질소 공여 화합물 및 전달체 시스템

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination